A Bristol-based company, which has developed faster and cheaper ways to identify harmful bacteria, has received financial backing from eight of the city’s successful entrepreneurs.
FluoretiQ, based in Unit DX in St. Philip’s, is a two-year-old business that is using novel technology to identify bacterial infections in hospitals, clinics and care homes. It sourced some of its latest financial support through Bristol Private Equity Club.
Chief executive, Neciah Dorh, who has a PhD in nanophotonics and a background in fluorescence technologies for bio-sensing, leads the team which has developed the techniques.
He said: “This support will enable us to push forward with our ambitious growth plans to revolutionise bacterial diagnostics. We are passionate about our research and development and have invested in building the team we need to deliver this technology to people all over the world.
“The technology can reduce clinical decision-making time from 48 hours to 15 minutes, an accelerated approach to existing care pathways. At the moment we are working on a solution for urinary tract infections, to reduce recurrent GP visits, hospitalisation and unnecessary prescription of broad spectrum antibiotics.
“We have always worked closely in collaboration with the University of Bristol and to now have other Bristol-based entrepreneurs recognising the potential of FluoretiQ is a huge boost and encouragement to us as a business.”
Jerry Barnes, founder of Bristol Private Equity Club, said: “Bristol is fast gaining a reputation for the number of companies like FluoretiQ that are using emerging technology to make a real difference to the world.
“We have 80 successful entrepreneurs and business people with capital in the club. They all want to support fast-growing and successful businesses and to share the expertise and lessons they have learned over the years with those at the leading edge of development.”
Bristol Private Equity Club has now invested a total of £6m in three years in 19 Bristol area businesses.
FluoretiQ was developed with venture capital from Deepbridge Capital and now has a strong scientific team taking the research forward.